{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021352","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.310601+00:00","generated_at":"2026-06-02T12:28:25.311656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive","bullets":["Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.","Cash $262.9M at March 31, 2024, up from $220.2M; net $63.5M raised via ATM and warrants.","COMP360 phase 3 for TRD on track: COMP005 top-line Q4 2024, COMP006 mid-2025.","Phase 2 PTSD open-label: 25mg single dose well tolerated; CAPS-5 reduction 29.9 pts at week 4.","Michael Gold joins as Chief R&D Officer May 20; Trevor Mill departs as Chief Development Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021352","json":"https://secwatch.observer/filing/0001628280-24-021352.json","markdown":"https://secwatch.observer/filing/0001628280-24-021352.md","text":"https://secwatch.observer/filing/0001628280-24-021352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/0001628280-24-021352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/cmps-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:28:25.311656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"262701d2545e42a10be247fba9c40c5b11ffe290","claim":"COMPASS Pathways plc reported three months ended March 31, 2024 results: net income $35.2 million, EPS $0.55 loss per share. Guidance initiated.","evidence_excerpt":"Net loss for the three months ended March 31, 2024, was $35.2 million, or $0.55 loss per share (including non-cash share-based compensation expense of $5.1 million), compared with $24.2 million, or $0.57 loss per share, during the same period in 2023 (including non-cash-share-based compensation expense of $4.1 million).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/0001628280-24-021352-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Net income","value":"$35.2 million"},{"label":"EPS","value":"$0.55 loss per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}